- Home
- FTHM vs PMN Comparison
FTHM vs PMN Comparison
Compare FTHM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | PMN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 131.5M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FTHM | PMN |
|---|---|---|
| Price | $0.59 | $13.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 82.7K | 33.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.29 |
| 52 Week High | $3.37 | $27.40 |
Technical Indicators
Market Signals| Indicator | FTHM | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 46.88 |
| Support Level | $0.57 | $12.89 |
| Resistance Level | $0.71 | $14.77 |
| Average True Range (ATR) | 0.04 | 1.22 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 13.33 | 32.81 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.